Against Veeva's 50.24 trailing P/E and 36.06 EV/EBITDA, SLP's forward 12.05x EV/EBITDA appears to price a mid-teens earnings profile rather than premium growth, which seems reasonable given that revenue growth has decelerated to 7.5% year over year from the 22-30% pace of mid-2025. The 4.73x P/S multiple is harder to justify on fundamentals alone: with net margin at 16.3% in 2026Q3, revenue multiples must be supported by durable margin expansion, yet gross margin has swung between 36.6% and 72.2% over ten quarters, so investors should not assume the current multiple reflects structural quality. The 2.98x price-to-book deserves special caution since retained earnings remain negative after the impairment, meaning book value is a depressed, non-economic denominator that inflates the apparent premium.

The most reliable measure of earning power here is probably not the reported operating margin but the mid-cycle gross margin, which returned to 69.1% in 2026Q3 after a 36.6% trough in 2024Q4, suggesting the true earnings anchor sits somewhere between those extremes rather than at the current print. Net margin of 16.3% also overstates economics when compared against peer Certara at -0.4% and Veeva at 28.4%, positioning SLP as a mid-tier earner whose profitability depends heavily on which projects fall into a given quarter. One adjustment worth monitoring is stock-based compensation, which consumed roughly 47% of net income in 2026Q3, implying that cash-based operating profitability is materially thinner than the net margin headline suggests.

With ROE at just 2.6% in 2026Q3 versus Veeva's 14.0%, SLP appears to be generating far less value per unit of capital than the market's 21x forward earnings multiple implies. The low ROIC reflects both depressed profitability in the post-impairment base and an asset base still dominated by goodwill, which does not contribute economically to returns unless the acquired businesses earn adequate spreads on capital. Investors should treat any recovery toward mid-single-digit or better ROIC as confirmation that the 2024Q4 acquisition is finally earning its cost of capital; continued sub-5% returns would suggest capital is being held below the company's own hurdle.

The zero-debt capital structure means leverage is not a live risk factor for SLP, and the 5.54x current ratio, backed by $35.3M of cash, provides a substantial buffer even in scenarios where revenue growth continues to decelerate. The trade-off is that the balance sheet offers no financial leverage to amplify equity returns, which partly explains why ROE of 2.6% trails peers' more leveraged capital structures despite similar asset intensity. Analysts should note that with debt at immaterial levels, the debt-to-equity and debt/EBITDA ratios carry little analytical signal for this business; the relevant capital-allocation question is whether the $35.3M cash pile will be deployed toward accretive acquisitions that repair the impaired goodwill balance rather than held idle.

The wide DSO band suggests collection timing on large pharma contracts, rather than operational inefficiency, is the primary driver of quarter-to-quarter cash swings, consistent with working capital changes having moved from -$5.4M to +$2.4M over the observed window. Asset turnover of just 0.09-0.17 on a quarterly basis reflects an intangible-heavy asset base rather than poor operating intensity, since capital expenditure is only 0.4% of revenue, confirming an asset-light model where the real constraint is revenue conversion, not asset utilization. Investors should be wary of inferring working-capital leverage from DPO, which has been inconsistently reported; the available data does not support conclusions about supplier payment terms or customer leverage.